All News

2017

September

Media Release / Sep 28, 2017

Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

Read More

August

Media Release / Aug 24, 2017

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More

June

Media Release / Jun 23, 2017

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More
Media Release / Jun 02, 2017

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

Read More

May

Media Release / May 31, 2017

Progress reported in global fight against diarrheal disease cryptosporidiosis

Read More
Media Release / May 31, 2017

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Read More
Media Release / May 30, 2017

Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

Read More
Media Release / May 18, 2017

Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care

Read More

March

Media Release / Mar 13, 2017

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Read More
2016

December

Media Release / Dec 09, 2016

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More